文献速递肿瘤 PET/CT

不可切除IIIA-IIIB期肺鳞癌患者根治性同步放化疗前行PET-CT的临床效果

Clinical Effects of PET-CT Before Definite Concurrent Chemoradiotherapy in Patients With Unresectable Stage IIIA-IIIB Squamous Cell Carcinoma of the Lungs.
PubMed 文献 · Clin Nucl Med · 2022-06-10

本研究为大规模回顾性队列研究,纳入不可切除IIIA-IIIB期肺鳞癌接受根治性同步放化疗的患者,按1:1匹配为放化疗前接受18F-FDG PET-CT组与未接受组,最终队列4042例(两组各2021例)。多变量Cox回归显示,放化疗前18F-FDG PET-CT与全因死亡呈正相关(调整风险比0.85,95%CI 0.80-0.91,P<0.0001)。结论认为放化疗前18F-FDG PET-CT与不可切除临床IIIA期和IIIB期接受根治性同步放化疗患者更有利的生存相关。

要点

  • 放化疗前18F-FDG PET-CT组与未接受组1:1匹配后各2021例,共4042例。
  • 多变量Cox回归:调整风险比0.85(95%CI 0.80-0.91,P<0.0001),与全因死亡呈正相关。
  • 结论认为放化疗前PET-CT与IIIA期和IIIB期患者更有利生存相关。

核心结论

  • 放化疗前18F-FDG PET-CT与不可切除IIIA-IIIB期肺鳞癌接受根治性同步放化疗患者更有利的生存相关。

研究设计与样本

  • 回顾性队列研究,纳入不可切除IIIA-IIIB期肺鳞癌接受根治性同步放化疗的患者,按1:1匹配分为放化疗前接受18F-FDG PET-CT组与未接受组。
  • 匹配后最终队列4042例,PET-CT组2021例,未接受PET-CT组2021例。

主要发现

  • 多变量Cox回归分析显示,放化疗前18F-FDG PET-CT与全因死亡呈正相关(调整风险比0.85,95%CI 0.80-0.91,P<0.0001)。
  • 结论认为放化疗前18F-FDG PET-CT与不可切除临床IIIA期和IIIB期接受根治性同步放化疗患者更有利的生存相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: No large-scale, retrospective cohort study with a long-term follow-up time has yet evaluated the effects of preoperative 18 F-FDG PET-CT on survival in patients with unresectable stages IIIA-IIIB squamous cell lung carcinoma (SqCLC) who received definite concurrent chemoradiotherapy (CCRT). METHODS: We included patients with unresectable stages IIIA-IIIB SqCLC receiving definite CCRT and categorized them into 2 groups. The case group comprised patients who underwent pre-CCRT 18 F-FDG PET-CT, and the comparison group comprised patients who did not receive pre-CCRT 18 F-FDG PET-CT; the groups were matched at a ratio of 1:1. RESULTS: The matching process yielded a final cohort of 4042 eligible patients (2021 and 2021 in the case and comparison groups, respectively). Multivariable Cox regression analyses revealed a positive correlation between patients with unresectable stages IIIA-IIIB SqCLC receiving definite CCRT and all-cause death in the pre-CCRT 18 F-FDG PET-CT (adjusted hazard ratio, 0.85; 95% confidence interval, 0.80-0.91; P < 0.0001). CONCLUSION: Pre-CCRT 18 F-FDG PET-CT was associated with more favorable survival in both patients with unresectable clinical stage IIIA and those with stage IIIB receiving definite CCRT.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Lin WC, Chen WM, Chen M, et al. Clinical Effects of PET-CT Before Definite Concurrent Chemoradiotherapy in Patients With Unresectable Stage IIIA-IIIB Squamous Cell Carcinoma of the Lungs. Clin Nucl Med. 2022. PMID: 35695702. doi:10.1097/RLU.0000000000004295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。